Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267236 | 0.83 | SLC7A5 (0.37) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4262731 | 0.82 | SLC7A5 (0.40) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL21411541 | 0.80 | SLC7A5 (0.34) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL125178 | 0.80 | SLC7A5 (0.34) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL597569 | 0.79 | SLC7A5 (0.33) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL8740472 | 0.77 | SLC7A5 (0.39) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL7200971 | 0.77 | SLC7A5 (0.39) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL3284389 | 0.76 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL29436333 | 0.76 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL2389248 | 0.76 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9644014-B2 | Modified animal erythropoietin polypeptides and their uses | AMBRX, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | HELICORE BIOPHARMA INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250276080-A1 | GLUCAGON RECEPTOR AGONISTS AND CONJUGATES TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTAGONISTS | AMGEN INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250121056-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | AMGEN INC. | 2025-04-03 | — | — | US | disclosed |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4480537-A2 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4429710-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | Amgen Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3570885-B1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | AMGEN INC (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2006091231-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | AMBRX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074650-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | AMBRX, INC. (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | IFNG, IFNAR1, EIF2AK2 | SLC7A5 4312/4885PKM 3762/4885PTGS1 3376/4885 |
| US-20250276080-A1 | GLUCAGON RECEPTOR AGONISTS AND CONJUGATES TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTAGONISTS | GIPR, GCGR, GLP1R | SLC7A5 2150/4885PKM 1952/4885PTGS1 3004/4885 |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | CTSD, DNPEP, CTSZ | SLC7A5 573/4885PKM 4496/4885PTGS1 4766/4885 |
| US-20250121056-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | GIPR, GLP1R, GCGR | SLC7A5 2257/4885PKM 3275/4885PTGS1 3360/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | SLC7A5 3346/4885PKM 4405/4885PTGS1 4523/4885 |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | GIPR, GLP1R, GPR119 | SLC7A5 2436/4885PKM 4762/4885PTGS1 4639/4885 |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | GHRHR, VEGFA, SHBG | SLC7A5 2131/4885PKM 1686/4885PTGS1 708/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | SLC7A5 345/4885PKM 684/4885PTGS1 3535/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | SLC7A5 284/4885PKM 3021/4885PTGS1 3028/4885 |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | FGF1, FGF2, FGF23 | SLC7A5 1753/4885PKM 4136/4885PTGS1 1524/4885 |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | GHITM, HDGF, GHRHR | SLC7A5 557/4885PKM 3259/4885PTGS1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.